US2017239265A1PendingUtilityA1
Drug for preventing and/or treating polycystic kidney disease
Est. expiryMay 31, 2032(~5.9 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 13/12A61P 13/00A61K 31/55A61K 45/06A61K 38/31A61K 9/0053A61K 9/0019A61K 38/10
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
Claims
exact text as granted — not AI-modified1 - 3 . (canceled)
4 . A method for treating polycystic kidney disease, comprising administering tolvaptan or a prodrug thereof in combination with at least one member selected from the group consisting of pasireotide, lanreotide, vapreotide and a salt thereof to a polycystic kidney disease patient.
5 . The method according to claim 4 , wherein the tolvaptan or prodrug thereof is orally administered, and said at least one member selected from the group consisting of pasireotide, lanreotide, vapreotide and a salt thereof is subcutaneously or intramuscularly administered to the polycystic kidney disease patient.
6 . The method according to claim 4 , wherein the dose of tolvaptan or a prodrug thereof is less than an effective dose when used alone.
7 . The method according to claim 5 , wherein the dose of tolvaptan or a prodrug thereof is less than an effective dose when used alone.Join the waitlist — get patent alerts
Track US2017239265A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.